An increasing number of studies suggest that mGluR1 PAMs could be applied in treating positive and cognitive symptoms of schizophrenia what is consistent with the hypothesis of mGluR1 contribution to the regulation of long-term potentiation (LTP) [40,41,42]. This evidence concerns the gene GRM1 and schizophrenia.